Login
$OKYO
$1.18 +$0.00 (0.0%) After hours

Company Executives

Management Team

From Forms 3, 4 and 5 filed in the last 18 months
Officer Source
Robert John Dempsey
CHIEF EXECUTIVE OFFICER
Title from the Form 4/A dated Jul 22, 2026
Keeren Rameshchandra Shah
Chief Financial Officer
Title from the Form 4 dated Jun 8, 2026
Rajkumar V. Patil
Chief Scientific Officer
Title from the Form 4/A dated Jul 27, 2026
Flavio Mantelli
CHIEF MEDICAL OFFICER
Title from the Form 4/A dated Jul 21, 2026
Gary S Jacob
CHIEF DEVELOPMENT OFFICER
Title from the Form 4/A dated Jul 21, 2026

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Board of Directors

We could not read this board reliably

Rather than show a list that might be wrong, we show nothing. The board is in the 20-F filed Jul 20, 2026.

Read the board in the 20-F

No proxy statement on record

Related-party transactions come from the company’s proxy statement. OKYO Pharma Ltd has not filed one with the SEC.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support